RxDoctor Payments Data

Neil Makadia, MD

Family Medicine · Canal Winchester, OHNPI 1760685242

Payments from drug & device makers

$8,494in general payments, 2019–2025

Across 610 payments — averaging $13.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$733
  • Novo Nordisk$698
  • Pfizer$569
  • AstraZeneca$538
  • Merck$515
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$8,470100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,494 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$65,702
Medicare patients
120
Services billed
2,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$48,263
EliquisApixaban27$31,068
XareltoRivaroxaban27$28,553
TrulicityDulaglutide11$26,467
JanuviaSitagliptin Phosphate12$19,484
JardianceEmpagliflozin11$11,108
Breo ElliptaFluticasone/Vilanterol12$6,587
Albuterol Sulfate HfaAlbuterol Sulfate122$4,425
Duloxetine Hcl37$2,688
Sumatriptan Succinate18$2,616
Atorvastatin Calcium185$2,611
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen59$1,996
Gabapentin83$1,689
Metoprolol Succinate84$1,377
SynthroidLevothyroxine Sodium15$1,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$186$54,85161 claims
PfizerEliquis$569$31,06827 claims
Johnson & JohnsonXarelto$101$28,55327 claims
Lilly USA, LLCTrulicity$733$26,46711 claims
MerckJanuvia$515$19,48412 claims
Boehringer IngelheimJardiance$174$11,10811 claims
AbbVieSynthroid$1,443$1,32615 claims
Almatica Pharma LLCSertraline Hcl$29$51635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Canal Winchester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →